How GLP-1 Medicines Work within the Intestine
“These medication gradual gastric emptying, assist folks really feel fuller longer, and may cut back general meals consumption, which is why they might be efficient for weight reduction,” says Danielle Gaffen, RDN, the San Diego–primarily based founding father of Eat Properly Crohn’s Colitis, which gives customized diet counseling for folks residing with IBD and different digestive circumstances.
Whereas weight reduction is a part of the enchantment of those medicines, that may be sophisticated for folks with UC. Weight in UC tends to be extremely variable, Gaffen says.
Some folks with UC wrestle with unintentional weight reduction throughout flares. However others could acquire weight because of restricted secure meals, decreased train due to signs, or medicines that may enhance urge for food and cravings, like corticosteroids, Gaffen says. For them, GLP-1s could supply an extra software for weight administration that may be tough to attain by means of food regimen and train alone.
There’s additionally rising curiosity in how these medicines could affect irritation within the intestine, which is a key driver of UC.
- A research revealed in 2023 discovered that GLP-1 medicines could assist cut back irritation and strengthen the intestine lining in folks with UC, although it notes that a lot of the proof up to now comes from animal and lab-based research, not giant trials in folks.
- A evaluate revealed in 2025 within the Journal of Crohn’s and Colitis means that GLP-1 medicines have each metabolic and anti inflammatory advantages for folks with IBD, with early research linking them to improved outcomes like fewer hospitalizations.
- A big real-world research revealed in 2026 within the journal Inflammatory Bowel Ailments discovered that GLP-1 use in folks with UC and Crohn’s illness was linked to decrease charges of steroid use, hospitalization, and intestinal surgical procedure. The researchers used the Mayo Clinic Platform, a healthcare database overlaying 8 million sufferers, to seek out about 580 folks with IBD who had taken GLP-1 medication. They word that their findings are observational and want affirmation in scientific trials.
Even with these promising outcomes, the analysis has an extended strategy to go, Moss says. “I’d name the information intriguing however not but follow altering,” he says.
